Clinical Trials Browser

Phase 3 × Has results × Fulvestrant × Clear all

NCT04650581 2026-04-13

FINER

Phase 3 Active not recruiting

250 enrolled 13 charts

Breast Neoplasms

NCT00099437 2026-03-18

CONFIRM

Phase 3 Active not recruiting

736 enrolled 14 charts

Breast Neoplasms

NCT05654623 2026-03-18

VERITAC-2

Phase 3 Active not recruiting

624 enrolled 17 charts

Breast Neoplasms

NCT01602380 2026-02-27

FALCON

Phase 3 Completed

462 enrolled 20 charts

Neoplasm Metastasis, Neoplasms

NCT02947685 2026-02-12

PATINA

Phase 3 Active not recruiting

518 enrolled 15 charts

Breast Neoplasms

NCT02763566 2026-02-05

MONARCH plus

Phase 3 Active not recruiting

463 enrolled 20 charts

Breast Neoplasms

NCT04305496 2026-01-29

CAPItello-291

Phase 3 Active not recruiting

818 enrolled 19 charts 2 FDA

Locally Advanced (Inoperable) or Metastatic Breast Cancer

NCT05169567 2026-01-16

postMONARCH

Phase 3 Active not recruiting

368 enrolled 14 charts

Breast Neoplasms, Neoplasm Metastasis

NCT02107703 2025-10-21

MONARCH 2

Phase 3 Active not recruiting

669 enrolled 22 charts 1 FDA

Breast Neoplasms

NCT03778931 2025-09-15

EMERALD

Phase 3 Completed

478 enrolled 16 charts 2 FDA

Breast Neoplasms

NCT04975308 2025-07-11

EMBER-3

Phase 3 Active not recruiting

874 enrolled 29 charts 3 FDA

Breast Neoplasms, Neoplasm Metastasis

NCT00253422 2025-06-04

SoFEA

Phase 3 Completed

698 enrolled 19 charts

Breast Neoplasms

NCT02437318 2025-02-13

SOLAR-1

Phase 3 Completed

572 enrolled 22 charts 2 FDA

BreastEndocrine

Breast Neoplasms, Neoplasms, Multiple Endocrine Neoplasia Type 1

NCT02028507 2024-09-25

PEARL

Phase 3 Completed

693 enrolled 40 charts

Breast Neoplasms

NCT01942135 2024-04-04

PALOMA-3

Phase 3 Completed

521 enrolled 31 charts

Breast Neoplasms

NCT02422615 2023-11-30

MONALEESA-3

Phase 3 Completed

726 enrolled 17 charts 2 FDA

BreastEndocrine

Breast Diseases, Breast Neoplasms, Neoplasms, Neoplasms by Site, Multiple Endocrine Neoplasia Type 1

NCT00545077 2023-03-31

Bevacizumab + Endocrine Treatment vs Endocrine Treatment as First Line in Postmenopausal Women

Phase 3 Completed

380 enrolled 21 charts

Breast Neoplasms

NCT00543127 2023-03-10

Fulvestrant (Faslodex) + Anastrozole (Arimidex) vs Anastrozole

Phase 3 Terminated

870 enrolled 17 charts

Breast Neoplasms

NCT02340221 2022-07-12

SANDPIPER

Phase 3 Terminated

631 enrolled 49 charts

Breast Neoplasms

NCT02137837 2021-01-28

S1222 Trial (Everolimus, Anastrozole and Fulvestrant) in Post-Menopausal Stage IV Breast Cancer

Phase 3 Terminated

37 enrolled 16 charts

Breast Neoplasms

NCT00075764 2021-01-13

S0226 Anastrozole With or Without Fulvestrant as First-Line Therapy in Postmenopausal Women With Metastatic Breast Cancer

Phase 3 Completed

695 enrolled 15 charts

Breast Neoplasms

NCT01610284 2020-08-25

BELLE-2

Phase 3 Completed

1,147 enrolled 20 charts

Breast Neoplasms, Neoplasm Metastasis

NCT00390455 2019-12-20

Fulvestrant With or Without Lapatinib in Treating Postmenopausal Women With Stage III or Stage IV Breast Cancer That is Hormone Receptor-Positive

Phase 3 Completed

295 enrolled 18 charts

Breast Neoplasms

NCT01633060 2019-01-30

BELLE-3

Phase 3 Terminated

432 enrolled 20 charts

Breast Neoplasms, Neoplasm Metastasis, Hereditary Sensory and Autonomic Neuropathies

NCT01300351 2015-04-24

Comparing the Efficacy and Tolerability of Fulvestrant 500 mg Versus 250 mg in Advanced Breast Cancer Women

Phase 3 Completed

249 enrolled 16 charts

Breast Neoplasms

NCT00256698 2012-08-01

FACT

Phase 3 Completed

514 enrolled 13 charts

Breast Neoplasms, Neoplasms, Recurrence